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It is now accepted that an overwhelming inflammatory response is the cause of human deaths
from avian H5N1 influenza infection. With this in mind we sought to examine the literature for
examples of complementary and alternative medicines that reduce inflammation, and to place
the results of this search in the context of our own work in a mouse model of influenza disease,
using a pharmaceutical agent with anti-inflammatory properties. Two Chinese herbs, Angelica
sinensis (Dang Gui) and Salvia miltiorrhiza (Danshen), have been recently shown to protect
mice during lethal experimental sepsis via inhibition of the novel inflammatory cytokine High
Mobility Group Box 1 protein (HMGB1). Biochanin A, a ligand of the peroxisome proliferator
activated receptors (PPAR) alpha and gamma and the active isoflavone in Trifolium pratense
(red clover), has anti-inflammatory properties, and thus could be used as an influenza treat-
ment. This is of great interest since we have recently shown that gemfibrozil, a drug used to
treat hyperlipidemia in humans and a synthetic ligand of PPAR alpha, significantly reduces the
mortality associated with influenza infections in mice. The inflammation-modulating abilities of
these natural agents should be considered in light of what is now known about the mechanisms
of fatal influenza, and tested as potential candidates for influenza treatments in their own right,
or as adjunct treatments to antivirals.
Keywords: High Mobility Group Box 1 protein – inflammatory response – red clover –
traditional Chinese medicine
Introduction
It is now generally accepted that the infectious agent in
isolation does not cause the illness and fatal outcome
seen in acute systemic infectious diseases. Instead, the
pathogen induces host cells to generate excessive amounts
of pro-inflammatory cytokines, the prototypic example
being tumor necrosis factor (TNF), that alter organ func-
tion and host metabolism, thus generating the disease we
observe (1,2). This general concept, originally proposed
to describe the severe disease caused by malaria infection
(3), then sepsis (4) and influenza (5), has taken root in the
mainstream, and is now often referred to as the ‘cytokine
storm’ (6).
Influenza researchers have embraced the cytokine
storm mechanism as an explanation for the fatal human
disease caused by avian H5N1 influenza (7–9). Likewise,
the pandemic influenza outbreak of 1918 is likely to have
induced an overwhelming and fatal cytokine response in
humans, as mice and monkeys infected with a recon-
structed 1918 influenza virus exhibited a dysregulated
immune response and hypercytokinemia, which leads to
death (10–12). The inevitable 3–6-month delay in vaccine
availability in the event of a pandemic (13) means that
treatments to prevent death (but not necessarily infection)
are a necessity. Existing problems with antiviral drugs
(stockpiles not big enough to treat populations, drugs
need to be taken prophylactically or very soon after
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necessitate investigation into other treatments (14).
Targeting the detrimental host response generated by
particularly pathogenic strains of influenza virus would
allow disease severity to be reduced to the point where
people will be sick, but will not die as a result of infec-
tion. We see agents with an ability to damp inflammatory
cytokine release [be they natural or pharmaceutical (15)]
as ideal candidates for influenza disease treatments,
particularly during the period while a new vaccine is
being generated, and as useful adjunct treatments to anti-
virals. As has been suggested for statins (16), using agents
that are in use in the human population for the treatment
of other conditions means that the safety of such agents
is already established, as is the optimal human dose
range.
A New Pharmaceutical Treatment for
Severe Influenza?
We have found that the pharmaceutical agent, gem-
fibrozil, already used in the human population to treat
hyperlipidemia, protects a significant proportion of mice
infected with influenza virus (H2N2) from developing
a fatal disease (17). Gemfibrozil belongs to the fibrate
class of drugs, which, like statins, are used to lower
blood lipid levels, although fibrates differ in their mech-
anism of action. Gemfibrozil is a synthetic ligand for
the peroxisome proliferator activated receptor (PPAR)
alpha. This nuclear receptor controls lipid homeostasis,
with fatty acids and eicosanoids as endogenous ligands
(18,19). We chose gemfibrozil for its known ability to
reduce release of inflammatory cytokines, including
TNF, interleukin (IL)-6 and interferon-g (IFN-g), as
well its ability to inhibit the nuclear translocation
of the transcription factor nuclear factor k-B (NF-kB)
(20–22), and hypothesized that these drug side-effects
might be useful in ameliorating influenza disease, as has
already been suggested (23). We have found that the pro-
tective ability of gemfibrozil during influenza infections is
likely to be a fibrate class effect, since fenofibrate also
reduces the mortality of influenza virus-infected mice
(unpublished data). Gemfibrozil lowers serum IL-6
levels in mice infected with influenza virus (unpublished
data) but its effects on other aspects of the host immune
response are not yet known, and remain the subject of
our further study.
It is important to note that the use of fibrates and
statins in the human population for lipid-lowering has
not, to our knowledge, enhanced susceptibility to viral
disease. This is probably due to the fact that the innate
antiviral response to infection, for example expression of
the antiviral protein, Mx, is regulated by type I interfer-
ons and not by TNF or IL-1 (24). While TNF has been
reported to exert direct antiviral effects against influenza
virus in vitro (25) its antiviral effects in vivo are less
clear. Administration of neutralizing anti-TNF antibodies
during the course of influenza in mice did not increase
viral titers, and the infection still resolved (26). Further-
more, the course of infection of H5N1 influenza virus
was not worsened in mice genetically unable to produce
TNF (27). It is therefore unlikely that agents that inter-
fere with expression of pro-inflammatory cytokines such
as TNF will enhance susceptibility to influenza, but this
remains to be experimentally tested.
The strategy of selecting agents with anti-inflammatory
properties need not only apply to pharmaceutical agents.
There are already precedents in the literature for the
use of natural agents to treat severe infections such as
influenza. Ginseng and Salviae (28) have been trialed for
their abilities to improve influenza vaccination outcomes
with good results, and may also modulate cytokines to
reduce immunopathology during influenza infections.
Researchers working during the SARS outbreak used
complementary medicines to treat a small number of
SARS patients with good results, and suggested that
these treatments might be useful in treating cases of
avian influenza (29,30). A recent review of the antiviral
and immunomodulatory effects of compounds isolated
from plants and traditional Chinese medicines describes
a Chinese study in which FM1 influenza virus-infected
mice were given the traditional Chinese medicine Yiqi
Qingwen Jiedu Heji (31). Researchers found that this
treatment reduced expression of the cytokines TNF,
IL-6 and IFN-g in the lungs of FM1 influenza-infected
mice, all of which are implicated in inflammation, and
increased levels of the anti-inflammatory cytokine
IL-10, the combined effect being a shortened course of
influenza disease (32). Glycyrrhizin, an active component
of liquorice roots, when given to mice from one day
before infection with influenza virus (H2N2), protected
all treated mice from fatality while all control mice
died (33). What is most interesting about this result
is that glycyrrhizin binds to, and inactivates, the novel
pro-inflammatory mediator High Mobility Group Box 1
protein (HMGB1) (34), which is elevated in the serum
of sepsis patients who succumbed to infection (35).
With these non-pharmaceutical precedents in mind, we
searched the literature for examples of complementary
and alternative medicines used to treat conditions other
than influenza that are characterized by increased
pro-inflammatory cytokine levels, for their potential to
mitigate the host response during severe influenza.
Looking Towards Other Conditions for Clues
Sepsis
Experimental models for sepsis provide an excel-
lent avenue for understanding pathophysiology and
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Because sepsis is characterized by a prolonged inflamma-
tory state that, if untreated, results in death (36), it is
comparable to the cytokine storm that ensues in H5N1
influenza infections in people. Any agents that have
proven to be of benefit in sepsis models should be con-
sidered as candidates for influenza treatments, and we
have found several examples in the literature of comple-
mentary medicines that do this.
The low molecular weight fraction of an aqueous
extract of the Chinese herb Angelica sinensis (Dang
Gui) is dose-dependently protective during lethal experi-
mental sepsis and endotoxemia (37). Ninety percent of
mice were saved during lethal endotoxemia (when only
30% of controls survived) when the extract was given
daily, and 70% of mice were saved during lethal sepsis
(when only 25% of controls survived) when the extract
was given daily. What is most impressive is that in the
sepsis model, the repeated administration of the extract
was not begun until 24h after the onset of sepsis, when
some animals had already died. The authors also showed
that this late administration significantly reduced serum
levels of HMGB1, and attributed the rescue of mice in
part to the attenuation of systemic HMGB1 accumula-
tion by the herbal extract. This effect on HMGB1 is
important as HMGB1 is the only high mobility group
protein with an additional extracellular function, a
cytokine-like activity (38,39). It is this function that
many researchers have become interested in since the
first demonstration in 1999 of the presence of high
levels of HMGB1 in the serum of mice and human
patients with sepsis (35). What is most unusual about
HMGB1 is that its secretion continues for an uncommon-
ly long time, with peak levels detected in cell cultures 18h
after stimulation (35). This is in contrast to TNF secre-
tion, for example, which peaks 90min after the initial
stimulus. In turn, once released into the circulation
HMGB1 generates a further wave of inflammatory cyto-
kine production (40) through its receptors, the receptor
for advanced glycation endproducts [RAGE; (41,42)],
and toll-like receptors 2 and 4 (43). This ability to amp-
lify and prolong inflammation is consistent with obser-
vations in sepsis where both HMGB1 and other
inflammatory cytokines are persistently elevated (44,45).
Recently, the same group of researchers showed that
the aqueous extract of another Chinese herb, Salvia
miltiorrhiza (Danshen), traditionally used to treat cardio-
vascular disorders, was also protective against lethal
endotoxemia and sepsis by decreasing HMGB1 levels
in vivo (46). As for the Dang Gui extract, the Danshen
extract was administered 24h after the onset of sepsis yet
still rescued mice. As a potential anti-influenza treatment
Danshen may have a double-pronged attack, as it also
possesses anti-viral activity (47,48).
Artemisinin, a Chinese herb traditionally used as
an anti-malarial drug, has been shown to possess
potent anti-inflammatory effects via inhibition of
NF-kB (49). It, too, protects against lethal endotoxemia
(50) thus warranting its consideration as a potential influ-
enza treatment. Chloroquine possesses antiviral (51) and
anti-inflammatory activities (52) and has already been
suggested as a potential treatment for pandemic
influenza (23).
Ginseng is another herb with potent anti-inflammatory
effects. An extract from Korean red ginseng (Panax
ginseng, C.A. Meyer) significantly protected mice in
experimental sepsis by decreasing TNF, IL-1, IL-6 and
IFN-g production via inhibition of NF-kB activation
(53–55). It is likely that Korean ginseng will also reduce
HMGB1 levels, because cytokines under the control of
NF-kB, such as TNF and IFN-g, induce HMGB1 (56).
Green tea (Camellia sinensis) reduces endotoxin-induced
release of HMGB1 and is also proposed to possess
the ability to decrease mortality from sepsis if taken
regularly (57).
Pancreatitis
Chronic pancreatitis is characterized by increased serum
levels of pro-inflammatory cytokines (58). Acute pancrea-
titis attacks are often followed by multiple organ failure
and death, due to the overproduction of inflammatory
cytokines (59) and like H5N1 influenza, the ‘cytokine
storm’ mechanism has been used to describe this syn-
drome (60). Serum levels of HMGB1 are known to
be elevated during acute pancreatitis (61). Danshen
(S. miltiorrhiza), described above as being protective
during experimental sepsis, also protects against acute
pancreatitis by reducing levels of reactive oxygen species
(62), downstream by-products of inflammation. Its use in
two syndromes that are characterized by an altered host
response, leading to multiple organ failure and death,
should make it a priority for influenza researchers inter-
ested in examining the effect of immunomodulatory treat-
ments on the course of influenza disease.
Menopause
Pro-inflammatory cytokines are increased during meno-
pause with ensuing pathologies including osteoporosis
and atherosclerosis (63). Red clover (Trifolium pratense)
isoflavone extracts are widely used for relieving post-
menopausal symptoms in women. Biochanin A is the
major isoflavone present in red clover, and activates
both PPAR alpha and gamma receptors in vitro (64).
Gemfibrozil, the synthetic PPAR alpha ligand that
increases survival of mice during severe murine influenza
(17), possesses anti-inflammatory side effects including
inhibition of NF-kB activity; this transcription factor is
essential for the transcription of pro-inflammatory genes
(21). Similarly, biochanin A has been recently shown to
decrease production of the pro-inflammatory cytokine
eCAM 2010;7(4) 503TNF, as well as its downstream mediators nitric oxide
and superoxide (65). The fact that biochanin A activates
both PPAR alpha and gamma would be an advantage in
treating severe influenza, as the PPAR gamma agonist
pioglitazone was recently shown to reduce the mortality
associated with PR8 influenza in mice (66). It is possible
that combining PPAR alpha and gamma activation in
one treatment, using biochanin A, may prove more
effective in curbing influenza-related mortality than
activation of either PPAR receptor alone.
The above examples of complementary medicines, used
in seemingly disparate syndromes to treat essentially
the same thing—pathological cytokine excess—should
provide researchers working in the influenza field with
a solid starting point for in vivo studies in animal
models of the disease.
A Traditional Chinese Formula Could Also
Protect Against Severe Influenza
Prescribed mixtures of Chinese herbs are given to patients
with influenza. A common formula contains Jin Yin Hua
(honeysuckle flower), Lian Qiao (forsythia fruit), Bo He
(field mint), Jing Jie (schizonepeta), Jie Geng (root
of balloon flower), Gan Cao (licorice root), Dang Gui
(A. sinensis root), Dang Shen (Codonopsis root), Chai
Hu (thorowax), Qianghuo (Notopterygium root) and
Sheng Jiang (fresh ginger rhizome). Intriguingly, nine of
these 11 herbs have been shown to possess anti-
inflammatory properties. A. sinensis is dose-dependently
protective during lethal experimental sepsis and endo-
toxemia (37) via its ability to limit release of HMGB1,
as has already been discussed. There are many examples
of Jie Geng (root of balloon flower), reducing both
production of pro-inflammatory cytokines and pro-
inflammatory mediators (such as reactive oxygen species
and nitric oxide), with these effects likely to be mediated
through suppression of activation of NF-kB [e.g. see
ref. (67)]. Sheng Jiang (fresh ginger rhizome), Gan Cao
(licorice root) and Lian Qiao (forsythia fruit) also reduce
levels of inflammatory cytokines via suppression of
NF-kB induction (e.g. see refs (68–70). Thus it seems
that a mixture of herbs, as traditionally prescribed,
is likely to have profound effects on the inflammatory
cytokine balance, warranting further investigation of the
mixture itself in vitro and in vivo.
Proposed Methodology
HMGB1 has a growing literature on its involvement
in the pathogenesis of severe inflammatory states. Large
amounts of HMGB1 have been detected in the serum
of sepsis patients who succumbed to infection (35).
Similarly, during falciparum malaria levels of HMGB1
are higher in patients who do not recover (71).
However recent observations paint a more complex pic-
ture of the significance of elevated serum HMGB1 mea-
surements. Sepsis patients with severe organ dysfunction
had the lowest serum HMGB1 levels of all sepsis patients
tested (72), which probably points to a well-known side-
effect of acute infection, immunosuppression. We have
shown that despite plasma levels of HMGB1 being
low at the time of peak mortality in mice infected with
A/Japan/305/57 influenza virus (H2N2), HMGB1 may be
elevated via its passive release in the lung at this time
(73). Therefore it would be important to first ascertain,
using animal models of influenza, how levels of HMGB1,
in the serum and/or lung, were associated with pathology
and/or fatality. Our own work in this area continues,
as does our focus on optimizing the way in which
HMGB1 is measured for study. Figure 1 shows the
likely sources and role of HMGB1 during infection
with influenza virus.
Therapeutic interventions in sepsis models, such as
administration of ethyl pyruvate (74), an agent that
limits HMGB1 release in vitro, or administration of an
anti-HMGB1 antibody (75), save a significant proportion
of mice, implicating the inhibition of HMGB1 release or
activity as a therapeutic target during immune pathology.
As previously mentioned, glycyrrhizin protects influenza
virus (H2N2)-infected mice from fatality (33) potentially
via its ability to bind to, and inactivate, HMGB1 (34).
Therefore it would be important to establish whether
or not therapeutic intervention with any of the agents
discussed here reverse the fatality of severe influenza
in animal models via effects on HMGB1 and/or other
aspects of the host response.
However, endogenously produced molecules that
dampen the effects of HMGB1 in the circulation are
also elevated during severe disease states. Thrombo-
modulin, which binds to HMGB1 and prevents it binding
to RAGE (76) is elevated during severe malaria (77),
sepsis (78,79) and influenza (80). Paradoxically, it is
this binding of HMGB1 to thrombomodulin that also
prevents activated protein C generation (81) and thus
its ensuing anti-inflammatory activities (82,83). Thus the
balance between HMGB1 and thrombomodulin in vivo
is likely to be important (81) and should also be deter-
mined as part of these studies.
A second, broader strategy could be to examine the
traditional Chinese medicine formula discussed here,
indeed, any other traditional formulas in their entirety,
for anti-inflammatory activity in vitro. Cultured mouse
macrophages could be stimulated with either commercial-
ly available recombinant influenza virus H5N1 haem-
agglutinin (HA) or LPS to induce production of
pro-inflammatory cytokines, in the presence or absence
of the formula, prepared as traditionally described
(simmered in boiling water for 45–60min). Cytokine
assays to profile pro- and anti-inflammatory cytokines
secreted over time into the culture supernatant could
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examine many different cytokines in each sample (such
as anti-inflammatory cytokines IL-4 and IL-10, and
pro-inflammatory cytokines IL-1, IL-2, IL-6, IL-8,
IL-17, IFN-g, TNF and HMGB1). Given results which
point towards levels of pro-inflammatory cytokines being
reduced by treatment of the cells with the formula, the
next step would be to conduct studies in mice infected
with influenza virus (such as mouse-adapted PR8) and
administered the formula orally, daily, adjusted accord-
ing to body weight. Parameters measured in the in vivo
experiments could initially include analysis of serum and
lung cytokine levels, body weight and temperature, and
even survival, providing researchers could interact with
their institutional ethics committee to arrive at a mutually
appropriate end-point for euthanasia for experiments of
this nature.
Systematic reviews of the literature on clinical trials
using traditional Chinese medicine in influenza patients
have demonstrated the need for proper design, using
randomized controlled trials and sufficiently large study
groups to gain meaningful results (84,85) as well as
a more systematic approach to disease diagnosis (86).
Thus it would be informative to take the insights
gained from results in mice into the clinic. Patients
hospitalized with influenza could be recruited [see
ref. (87) for parameters relating to recruitment] to a
randomized controlled trial to determine if treatment
with a traditional Chinese medicine formula (for example,
the formula previously discussed here) affected the
course of disease. It would be prudent to begin treatment
immediately, before laboratory confirmation of influenza
virus infection. This is because symptoms are apparent
at the time of increased serum cytokine levels (87).
Obviously patients testing negative to influenza virus
would subsequently be excluded from analysis. The
decoction would be prepared in the traditional manner
(simmering in boiling water for 45–60min) and adminis-
tered to patients by hospital staff. The control treatment
could simply be a flavored water solution that is stored in
the same way as the decoction (at 4C for not more than
1 week), and consumed daily in the same quantity as the
decoction. Both solutions should be colored identically
(with a food-grade dye, for example). It would be ideal
to ensure the trial was conducted in a double-blind fash-
ion so that neither the patient nor the staff knew which
treatment was active. Previous studies have compared the
incidence of influenza-like illness in healthcare workers
Figure 1. Amplification and prolongation of inflammation by high mobility group box 1 protein (HMGB1) during influenza. Influenza virus-infected
airway epithelial cells may passively release HMGB1 [see ref. (92) as an example], while alveolar macrophages, which become infected with influenza
virus (93), secrete pro-inflammatory cytokines and may also secrete HMGB1 both actively and passively. MIP is macrophage inflammatory protein.
Cytokines (excluding IL-10) commonly reported to be involved in pathogenesis were compiled from (94–96). IL-10 from effector T-cells was recently
shown to limit inflammation during acute influenza (97). HMGB1 up-regulates pro-inflammatory cytokine expression via its cellular receptors, the
receptor for advanced glycation end products [RAGE; (41,42,98)] and to a lesser extent, toll-like receptor (TLR) 2 and 4 (43,99). RAGE expression
was recently shown to be associated with influenza A virus pneumonia, accompanied by increased levels of HMGB1 in bronchoalveolar lavage
fluid (100).
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but results were questioned because workers given the
herbal formula knew that they were taking the ‘active’
treatment. While these trials recruited thousands of
patients, we suggest that patient numbers could be kept
relatively small in the first instance (20 patients per
group) if, in addition to patients being unaware of the
activity of the treatment they are given, daily blood
samples are taken to measure serum levels of cytokines,
as for the in vitro assays described above. One milliliter of
blood would provide enough serum to analyze cytokine
levels, and daily measurements on the same individual
would allow for paired statistical analysis. The appropri-
ate end-point would be convalescence, but obviously
if symptoms worsened with treatment (or control) then
standard interventions should immediately take place.
These basic but necessary experiments could pave the
way towards viable, low cost alternatives to planned
influenza pandemic treatments— approximately $8 for
a fortnight’s treatment (88). Figure 2 summarizes the
possible inflammation-reducing effects of traditional
Chinese medicines (e.g. A. sinensis, S. miltiorrhiza and
glycyrrhizin), a natural agent (biochanin A), and
pharmaceutical interventions (e.g. statins, fibrates),
during influenza.
A Note on Non-medicinal Interventions
Direct stimulation of the vagus nerve has been shown to
exert potent inflammation-reducing activities in the body
(89). Transcutaneous stimulation of the vagus nerve
improves survival in mice with sepsis by reducing serum
levels of HMGB1 (90). Thus there is a distinct possibility
that vagus nerve stimulation by acupuncture could con-
trol immune-mediated pathology, by limiting release
of pro-inflammatory cytokines. The potential for using
acupuncture in this way was recently reviewed (91) with
the authors noting that ‘the use of acupuncture as an
adjunct therapy to conventional medical treatment for
a number of chronic inflammatory and autoimmune
diseases seems plausible and should be validated by con-
firming its cholinergicity’. Thus stimulation of the vagus
nerve in patients with influenza could also represent an
adjunct treatment in the management of severe influenza
cases, provided it can be further investigated.
Figure 2. Potential mitigation of the action of HMGB1 and other pro-inflammatory cytokines by traditional Chinese medicines, a natural agent, and
pharmaceutical drugs. The Chinese medicine glycyrrhizin, from liquorice root, binds to HMGB1 and inactivates its biological activities (34), while the
Chinese herbs A. sinensis and S. miltiorrhiza reduce the release of HMGB1 (37,46). Release of pro-inflammatory cytokines is reduced via inhibition
of NF-kB activation, by glycyrrhizin (101–103), A. sinensis (104,105), and S. miltiorrhiza (106,107); by the natural agent biochanin A (65,108,109);
and the pharmaceutical drugs statins (110,111) and fibrates (21,112,113). Pro-inflammatory cytokine release is reduced by activation of PPARs
(21) and conversely, anti-inflammatory cytokine release is increased by their activation (114,115). PPAR alpha is activated by fibrates (21); PPAR
alpha and gamma are activated by biochanin A (64); and statins upregulate PPAR alpha and gamma and show molecular signaling properties similar
to fibrates (116).
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The example given here of an ancient Chinese medicine
formula used to treat influenza containing nine (out
of 11) herbs with anti-inflammatory properties provides
compelling evidence that the way forward for the treat-
ment of influenza in a pandemic should be immunomo-
dulation. The host response is targeted, rather than the
virus itself. Our observation that treatment of influenza
virus-infected mice with a pharmaceutical used in
humans, the lipid-lowering and immunomodulatory
PPAR alpha agonist gemfibrozil, resulted in significantly
decreased influenza-induced mortality, further shows
that targeting the host response is a valid possibility.
The natural immunomodulatory agent biochanin A
from Red Clover, which is both a PPAR alpha and
PPAR gamma agonist, could have similar effects to
gemfibrozil on the course of influenza disease in vivo.
Chinese herbs such as A. sinensis and S. miltiorrhiza
which independently reduce secretion of the novel inflam-
matory cytokine HMGB1, and glycyrrhizin from liquor-
ice root, which binds to HMGB1 and inactivates its
activity, provide another avenue for investigation, as
does the establishment of the role of HMGB1 in severe
influenza. The wide availability and low economic price
of these agents could make such agents an inexpensive
alternative treatment, particularly in countries with large
populations who will have no access to pandemic
vaccines or antivirals.
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